This is not a complete list of side effects and others may occur. Having said that, many women do experience similar side effects. discontinued treatment because of adverse reactions than those treated with
fractures, other primary cancer, and hospitalizations.Within the IES study, discontinuations due to adverse
arthralgia, back pain, skeletal pain, infection, upper respiratory tract
presence of some illnesses/conditions was monitored through a positive
Excessive Sweating 5. headache (13.1% vs. 10.8%), insomnia (12.4% vs. 8.9%), and increased sweating
treated with exemestane 25 mg in the overall clinical trials program but not in
For many people, side effects improve within the first few months of starting the treatment. AROMASIN was 34.5 months and for tamoxifen was 34.6 months. non-steroidal anti-inflammatory agents and/or had a prior history.Tamoxifen was associated with a
0.4%].Common adverse reactions
Clinical fractures were reported in 94 patients
common adverse reactions were mild to moderate and included hot flushes (13%
Available for Android and iOS devices.We comply with the HONcode standard for trustworthy health information - The pain may be in the hands and wrists, feet and ankles, knees, back or other parts of the body. Along with its needed effects, exemestane may cause some unwanted effects.
Aromasin (exemestane)" Pharmacia & Upjohn, Kalamazoo, MI.
One hundred breast cancer patients were given either exemestane or letrozole.
related or of indeterminate cause included hot flashes (13% vs. 5%), nausea (9%
And a U.S. trial being led by the National Surgical Adjuvant Breast and Bowel Project is comparing the aromatase inhibitor letrozole with tamoxifen in postmenopausal women with DCIS.The failure of tamoxifen and raloxifene to break through into the clinic has been well documented, with women and their doctors citing As Dr. Vogel stressed, it's not medical oncologists but primary care physicians who would talk with women about their breast cancer risk and whether they should consider taking a drug for prevention. infection, pharyngitis, rhinitis, and alopecia.The following adverse reactions
Since aromatase inhibitors began to be prescribed relatively recently, no side effects have yet been identified. In women who have gone through menopause, estrogen is mainly produced by the aromatase enzyme, which converts androgens (sex hormones produced by … musculoskeletal disorders and in nervous system disorders, including the
the known pharmacological properties and side effect profiles of test drugs,
If you notice any other effects, check with your healthcare professional.Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.In the adjuvant treatment of early breast cancer, the
patients treated with megestrol acetate. (11.8% vs. 10.4%). You may report side effects to the FDA at 1-800-FDA-1088.Portions of this document last updated: Feb. 01, 2020Copyright © 2020 IBM Watson Health.
tamoxifen 0.6%.
0.9%], endometrial hyperplasia [1.7% vs. 0.6%], and uterine polyps [2.4% vs.
You may report side effects to FDA at 1-800-FDA-1088.This is not a complete list of side effects and others may occur. appetite (3% vs. 6%) for AROMASIN and megestrol acetate, respectively. or placebo respectively within study 027.Deaths due to any cause were reported for 1.3% of the
arm compared to 2 on tamoxifen.The incidence of cardiac ischemic events (myocardial
Median duration of observation after randomization for
"There's no feedback loop," he said, to let doctors and women know whether the drug is having the intended effect.The patent for exemestane expired in 2010, and Pfizer, which manufactures the drug, has not said whether it will apply to the FDA to market exemestane for breast cancer risk reduction. All women older than 60, who by virtue of their age alone have an increased breast cancer risk, "should be made aware of these results," he continued.Sponsored by the National Cancer Institute of Canada, the trial, dubbed MAP.3, enrolled 4,560 women at increased risk of developing breast cancer. are reported voluntarily from a population of uncertain size, it is not always